Published in Antimicrob Agents Chemother on May 27, 2014
A continuous enzyme-coupled assay for triphosphohydrolase activity of HIV-1 restriction factor SAMHD1. Antimicrob Agents Chemother (2014) 0.97
SAMHD1 specifically affects the antiviral potency of thymidine analog HIV reverse transcriptase inhibitors. Antimicrob Agents Chemother (2014) 0.89
A High-Throughput Enzyme-Coupled Assay for SAMHD1 dNTPase. J Biomol Screen (2015) 0.82
Substrates and Inhibitors of SAMHD1. PLoS One (2017) 0.82
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat Med (2016) 0.81
Select host restriction factors are associated with HIV persistence during antiretroviral therapy. AIDS (2015) 0.81
Differential regulatory activities of viral protein X for anti-viral efficacy of nucleos(t)ide reverse transcriptase inhibitors in monocyte-derived macrophages and activated CD4(+) T cells. Virology (2015) 0.77
SAMHD1 enhances nucleoside-analogue efficacy against HIV-1 in myeloid cells. Sci Rep (2017) 0.75
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature (2011) 9.30
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature (2011) 7.92
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol (2012) 5.71
A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature (2010) 5.45
HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature (2011) 5.28
SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med (2012) 4.27
SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology (2007) 3.51
Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. J Biol Chem (2011) 3.21
Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J Biol Chem (2004) 3.10
SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells. Retrovirology (2012) 2.92
Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J Mol Biol (2008) 2.88
Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein. Cell Host Microbe (2012) 2.66
SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutières syndrome are highly susceptible to HIV-1 infection. PLoS Pathog (2011) 2.65
The bottleneck in AZT activation. Nat Med (1997) 2.61
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents (2008) 2.52
Structure and function of cellular deoxyribonucleoside kinases. Cell Mol Life Sci (2002) 2.31
Tight interplay among SAMHD1 protein level, cellular dNTP levels, and HIV-1 proviral DNA synthesis kinetics in human primary monocyte-derived macrophages. J Biol Chem (2012) 2.25
With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIV(MAC). Gene Ther (2006) 2.24
Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. J Exp Med (1988) 2.08
Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem (1994) 2.03
The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis (2004) 2.03
HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology (2009) 2.02
SAMHD1 restricts HIV-1 infection in dendritic cells (DCs) by dNTP depletion, but its expression in DCs and primary CD4+ T-lymphocytes cannot be upregulated by interferons. Retrovirology (2012) 1.96
Nuclease activity of the human SAMHD1 protein implicated in the Aicardi-Goutieres syndrome and HIV-1 restriction. J Biol Chem (2013) 1.95
Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem (1989) 1.89
Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr? Retrovirology (2010) 1.76
Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages. J Biol Chem (2010) 1.70
Contribution of SAM and HD domains to retroviral restriction mediated by human SAMHD1. Virology (2012) 1.68
Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res (2008) 1.56
A simple, versatile and efficient method to genetically modify human monocyte-derived dendritic cells with HIV-1-derived lentiviral vectors. Nat Protoc (2011) 1.54
Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid cells. Mol Pharmacol (1989) 1.54
Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor. J Biol Chem (2009) 1.45
2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int J Biochem Cell Biol (2008) 1.36
Host hindrance to HIV-1 replication in monocytes and macrophages. Retrovirology (2010) 1.33
Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol Sci (2002) 1.32
Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase. Viruses (2010) 1.24
Restriction of diverse retroviruses by SAMHD1. Retrovirology (2013) 1.23
Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase. AIDS Rev (2005) 1.22
Inhibitors of HIV-1 reverse transcriptase. Adv Pharmacol (2000) 1.20
Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmacotherapy (2001) 1.16
A computational model of mitochondrial deoxynucleotide metabolism and DNA replication. Am J Physiol Cell Physiol (2005) 1.10
Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. Antiviral Res (2006) 1.07
Identification and characterization of naturally occurring splice variants of SAMHD1. Retrovirology (2012) 1.02
Anti-HIV host factor SAMHD1 regulates viral sensitivity to nucleoside reverse transcriptase inhibitors via modulation of cellular deoxyribonucleoside triphosphate (dNTP) levels. J Biol Chem (2013) 1.02
Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine in vitro and in vivo. Antimicrob Agents Chemother (2012) 1.01
Cellular phosphorylation of anti-HIV nucleosides. Role of nucleoside diphosphate kinase. J Biol Chem (1996) 0.96
Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides. Drugs (2009) 0.93
Metabolism of 3'-azido-3'-deoxythymidine (AZT) in human placental trophoblasts and Hofbauer cells. Biochem Pharmacol (1994) 0.91
Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine. Antimicrob Agents Chemother (2013) 0.90
Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA. Retrovirology (2013) 0.90
The sugar ring conformation of 4'-ethynyl-2-fluoro-2'-deoxyadenosine and its recognition by the polymerase active site of HIV reverse transcriptase. Cell Mol Biol (Noisy-le-grand) (2011) 0.89
Structural basis for activation of alpha-boranophosphate nucleotide analogues targeting drug-resistant reverse transcriptase. EMBO J (2000) 0.88
Pre-steady state of reaction of nucleoside diphosphate kinase with anti-HIV nucleotides. J Biol Chem (1998) 0.87
Inhibitors of HIV-1 reverse transcriptase. Adv Pharmacol (2008) 0.85
The mechanism of phosphorylation of anti-HIV D4T by nucleoside diphosphate kinase. Mol Pharmacol (2000) 0.85
Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant. Cell Mol Biol (Noisy-le-grand) (2012) 0.84
Evaluation of combinations of 4'-ethynyl-2-fluoro-2'-deoxyadenosine with clinically used antiretroviral drugs. Antimicrob Agents Chemother (2013) 0.83
Mitochondrial AZT metabolism. IUBMB Life (2006) 0.83
Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine. Antimicrob Agents Chemother (2007) 0.82